Aristotle University Of Thessaloniki (AUTH)
The effect of biologic agents on metabolic associated fatty liver disease in patients with inflammatory bowel disease
Abstract
dc:descriptionIntroduction: Inflammatory bowel diseases (IBD) exhibit intestinal and systematic manifestations. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common co-existing condition with IBD, possibly contributing to the cardio-metabolic burden and overall morbidity observed in patients with IBD. Εmerging therapeutic choices of biologicals have modified the clinical course of IBD; however, their impact on IBD-associated MASLD has not been extensively evaluated. The prevalence of MASLD varies within patients with IBD, but it appears higher than in the general population in the majority of quality studies. IBD-associated MASLD possibly follows two different patterns, one manifested during the relapses and one during the remissions of IBD. Thus, the pathogenic and risk factors of MASLD may vary upon IBD activity. Dysbiosis of intestinal microbiota, mucosal damage, and cytokine release have been implicated in the pathogenesis during the relapses, whilst metabolic risk factors seem to play a key role during the remissions of IBD. Considering biologicals, although quality data are scarce, those suppressing tumour necrosis factor may offer potential benefits in IBD-associated MASLD, whereas those acting as anti-integrins do not appear to confer any therapeutic advantage to MASLD. Aim: This study primarily aimed to evaluate the six-month effect of infliximab or vedolizumab vs. no treatment with biologicals on hepatic steatosis in patients with IBD. Methods: For the needs of this prospective, open-label, non-randomized trial, patients starting treatment with infliximab or vedolizumab for IBD were recruited in active arms, whereas patients with IBD not receiving biologicals were recruited in the control arm. Parameters regarding IBD activity, hepatic steatosis, fibrosis, and non-invasive indices were also evaluated. Repeated measures ANOVA was used to evaluate the overall tendency of group×time interactions for continuous variables and binary regression analysis adjusted for potential covariates was used for dichotomous variables. Results: Sixty-six naïve patients for biologicals were allocated into three groups: infliximab (n: 26), vedolizumab (n: 14), and control (n: 26). At baseline, steatosis was present in 26.9% (infliximab), 46.2% (vedolizumab), and 23.1% (control). After six months, steatosis reduced in all groups, without significant difference in group×time interactions. Apart from waist circumference, other disease-related covariates and serological markers (adipokines, TNF, PIINP and TIMP-1) did not affect the group×time interactions of primary and secondary endpoints. Conclusion: No positive or negative effects of infliximab or vedolizumab compared to treatment without biologicals on presumed hepatic steatosis in patients with IBD was shown.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papaefthymiou, Apostolis
- Παπαευθυμίου, Αποστόλης
Subjects
dc:subject × 22- Ιδιοπαθή φλεγμονώδη νοσήματα του εντέρου
- Μη αλκοολική λιπώδη νόσος του ήπατος
- Νόσος Crohn
- Ελκώδης κολίτιδα
- Ινφλιξιμάμπη
- Βιολογικοί παράγοντες
- Βεντολιζουμάμπη
- Hepatic steatosis
- Inflammatory bowel diseases (IBD)
- Crohn's disease
- Ulcerative colitis
- Infliximab
- Vedolizumab
- Biological agents
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Γαστροεντερολογία
- Ηπατολογία
- Clinical Medicine
- Medical and Health Sciences
- Gastroenterology
- Hepatology
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/57833